BlossomHill Therapeutics
Update in progressBLSM (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BlossomHill Therapeutics, Inc. is a clinical‑stage biopharmaceutical company focused on developing small molecule medicines for cancer. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in trials for advanced EGFR-mutant non-small cell lung cancer; and BH-301/ BH-30236, including a macrocyclic CLK (Cdc2-like kinase) inhibitor studied in relapsed/refractory AML and higher-risk myelodysplastic syndrome. Incorporated in 2020, based in San Diego, CA.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.08
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!